Capital Research Global Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $197M | Buy |
3,491,386
+944,099
| +37% | +$55M | 0.03% | 237 |
|
|
2025
Q4 | $151M | Buy |
2,547,287
+9,691
| +0.4% | +$528K | 0.03% | 259 |
|
|
2025
Q3 | $137M | Buy |
2,537,596
+2,145,717
| +548% | +$123M | 0.03% | 269 |
|
|
2025
Q2 | $21.5M | Sell |
391,879
-8,758,776
| -96% | -$516M | ﹤0.01% | 391 |
|
|
2025
Q1 | $647M | Sell |
9,150,655
-3,841,117
| -30% | -$258M | 0.14% | 126 |
|
|
2024
Q4 | $854M | Buy |
12,991,772
+2,496,817
| +24% | +$167M | 0.18% | 114 |
|
|
2024
Q3 | $738M | Buy |
10,494,955
+802,389
| +8% | +$67.1M | 0.15% | 118 |
|
|
2024
Q2 | $798M | Buy |
9,692,566
+3,171,905
| +49% | +$264M | 0.18% | 111 |
|
|
2024
Q1 | $570M | Sell |
6,520,661
-4,253,980
| -39% | -$381M | 0.13% | 139 |
|
|
2023
Q4 | $1.04B | Buy |
10,774,641
+4,756,671
| +79% | +$421M | 0.26% | 88 |
|
|
2023
Q3 | $532M | Sell |
6,017,970
-738,062
| -11% | -$65.7M | 0.15% | 137 |
|
|
2023
Q2 | $586M | Sell |
6,756,032
-452,927
| -6% | -$42.6M | 0.16% | 130 |
|
|
2023
Q1 | $701M | Buy |
7,208,959
+1,557,958
| +28% | +$162M | 0.2% | 107 |
|
|
2022
Q4 | $585M | Buy |
5,651,001
+714,261
| +14% | +$67.1M | 0.18% | 122 |
|
|
2022
Q3 | $418M | Buy |
4,936,740
+1,394
| +0% | +$124K | 0.14% | 146 |
|
|
2022
Q2 | $409M | Sell |
4,935,346
-4,452,610
| -47% | -$355M | 0.13% | 149 |
|
|
2022
Q1 | $724M | Sell |
9,387,956
-3,284,052
| -26% | -$275M | 0.18% | 115 |
|
|
2021
Q4 | $1.12B | Sell |
12,672,008
-4,973,431
| -28% | -$410M | 0.25% | 94 |
|
|
2021
Q3 | $1.36B | Sell |
17,645,439
-4,440,950
| -20% | -$350M | 0.32% | 80 |
|
|
2021
Q2 | $1.84B | Buy |
22,086,389
+10,024
| +0% | +$795K | 0.43% | 57 |
|
|
2021
Q1 | $1.67B | Sell |
22,076,365
-2,592
| -0% | -$212K | 0.41% | 56 |
|
|
2020
Q4 | $1.94B | Buy |
22,078,957
+15,695
| +0.1% | +$1.24M | 0.5% | 41 |
|
|
2020
Q3 | $1.68B | Sell |
22,063,262
-2,514
| -0% | -$254K | 0.5% | 41 |
|
|
2020
Q2 | $2.72B | Buy |
22,065,776
+25,158
| +0.1% | +$2.5M | 0.86% | 26 |
|
|
2020
Q1 | $1.86B | Buy |
22,040,618
+36,553
| +0.2% | +$3.15M | 0.73% | 29 |
|
|
2019
Q4 | $1.86B | Buy |
22,004,065
+296,401
| +1% | +$22.4M | 0.56% | 46 |
|
|
2019
Q3 | $1.46B | Buy |
21,707,664
+2,011,459
| +10% | +$155M | 0.48% | 53 |
|
|
2019
Q2 | $1.69B | Buy |
19,696,205
+1,947,144
| +11% | +$167M | 0.54% | 50 |
|
|
2019
Q1 | $1.58B | Sell |
17,749,061
-555,102
| -3% | -$51.4M | 0.5% | 52 |
|
|
2018
Q4 | $1.56B | Sell |
18,304,163
-1,244,970
| -6% | -$118M | 0.54% | 51 |
|
|
2018
Q3 | $1.9B | Sell |
19,549,133
-2,043,999
| -9% | -$204M | 0.55% | 43 |
|
|
2018
Q2 | $2.03B | Buy |
21,593,132
+92,281
| +0.4% | +$8.08M | 0.56% | 46 |
|
|
2018
Q1 | $1.74B | Sell |
21,500,851
-8
| -0% | -$687 | 0.5% | 55 |
|
|
2017
Q4 | $1.92B | Buy |
21,500,859
+650,258
| +3% | +$56.5M | 0.56% | 52 |
|
|
2017
Q3 | $1.94B | Buy |
20,850,601
+1,951,902
| +10% | +$172M | 0.59% | 46 |
|
|
2017
Q2 | $1.72B | Sell |
18,898,699
-744,734
| -4% | -$67.8M | 0.54% | 49 |
|
|
2017
Q1 | $1.72B | Buy |
19,643,433
+390
| +0% | +$34.7K | 0.54% | 51 |
|
|
2016
Q4 | $1.63B | Sell |
19,643,043
-573,172
| -3% | -$49.3M | 0.53% | 54 |
|
|
2016
Q3 | $1.87B | Buy |
20,216,215
+4,362,912
| +28% | +$411M | 0.62% | 44 |
|
|
2016
Q2 | $1.23B | Buy |
15,853,303
+8
| +0% | +$680 | 0.42% | 65 |
|
|
2016
Q1 | $1.31B | Sell |
15,853,295
-2,134,806
| -12% | -$174M | 0.45% | 61 |
|
|
2015
Q4 | $1.88B | Sell |
17,988,101
-952,119
| -5% | -$99.4M | 0.64% | 42 |
|
|
2015
Q3 | $1.99B | Sell |
18,940,220
-697,601
| -4% | -$93.2M | 0.71% | 36 |
|
|
2015
Q2 | $2.69B | Buy |
19,637,821
+143,705
| +0.7% | +$17.8M | 0.88% | 25 |
|
|
2015
Q1 | $2.43B | Buy |
19,494,116
+1,429,587
| +8% | +$151M | 0.83% | 27 |
|
|
2014
Q4 | $1.63B | Buy |
18,064,529
+42,716
| +0.2% | +$3.55M | 0.55% | 44 |
|
|
2014
Q3 | $1.3B | Buy |
18,021,813
+145,800
| +0.8% | +$9.58M | 0.45% | 58 |
|
|
2014
Q2 | $1.11B | Buy |
17,876,013
+98,420
| +0.6% | +$5.95M | 0.39% | 69 |
|
|
2014
Q1 | $1.21B | Buy |
17,777,593
+356,609
| +2% | +$26.3M | 0.44% | 62 |
|
|
2013
Q4 | $1.22B | Buy |
17,420,984
+74,300
| +0.4% | +$5.05M | 0.45% | 61 |
|
|
2013
Q3 | $1.25B | Buy |
17,346,684
+377,938
| +2% | +$25.1M | 0.49% | 54 |
|
|
2013
Q2 | $947M | Buy |
+16,968,746
| New | +$1.06B | 0.4% | 69 |
|
Other funds holding BMRN
VCM
VPM
Capital Research Global Investors's BMRN Position: Q1 2026 in Review
Capital Research Global Investors increased its BioMarin Pharmaceuticals (BMRN) stake by 37% in Q1 2026, buying an estimated $55M and bringing the position to 3,491,386 shares worth $197M. The position accounts for 0.03% of the portfolio, ranked #237.
Capital Research Global Investors first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.72B in Q2 2020. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Capital Research Global Investors held 3,491,386 shares of BioMarin Pharmaceuticals worth $197M as of Q1 2026.
- Capital Research Global Investors bought 944,099 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $55M.
- BioMarin Pharmaceuticals made up 0.03% of Capital Research Global Investors's portfolio in Q1 2026, its #237 holding.
- Capital Research Global Investors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Capital Research Global Investors's BioMarin Pharmaceuticals position peaked at $2.72B in Q2 2020.
- 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.